

# The Association between Platelet Lymphocyte Ratio and In-Hospital Outcomes in Patients with First Attack of Acute ST-elevation Myocardial Infarction following Thrombolysis with Streptokinase

## Abstract

**Background:** Platelet Lymphocyte ratio (PLR) has been found to be a good predictor of future adverse cardiovascular outcomes in patients with ST-segment elevation myocardial infarction (STEMI). **Objective:** Aimed to investigate the role of Platelet Lymphocyte ratio (PLR) in predicting in-hospital adverse cardiac events in patients with STEMI thrombolysed with streptokinase. **Methodology:** This cross sectional descriptive study carried out in the Department of Cardiology, Mymensingh Medical college Hospital, Mymensingh for fifteen month duration from January, 2018 to March, 2019, in STEMI patients, who were thrombolysed with inj. Streptokinase (STK) had blood samples at admission, analysed complete blood counts for PLR calculation. They were grouped into two, low and high PLR, taking 150 as cut-off. Chi square test was used to compare rate of adverse events and death in hospital stay. Logistic regression analysis was used to estimate predictive ability of PLR for in-hospital cardiac events. **Results:** A total of 79 (%) patients had complications. Patients in high PLR group had higher rate of complications (63.6% vs. 21.4%,  $p < 0.001$ ) in hospital than those in low PLR group. Arrhythmias (13.0% vs. 5.0%,  $p < 0.036$ ), Heart failure (45.5% vs. 15.0%,  $p = 0.001$ ), Cardiogenic shock (10.4% vs. 3.6%,  $p < 0.001$ ), Death (9.1% vs. 6.4%,  $p = 0.473$ ), occurred more in high PLR group. Mean PLR was significantly different between group-I and group-II ( $96.21 \pm 27.79$  vs.  $233.21 \pm 88.20$ ,  $p < 0.001$ ). Multivariate regression analysis showed PLR an independent predictor of in-hospital adverse cardiac events (at 10% level of significance,  $p = 0.001$ ). **Conclusion:** High admission PLR is an independent predictor for in-hospital adverse cardiac events in patients hospitalised for STEMI thrombolysed with streptokinase.

**Key Words:** Platelet Lymphocyte ratio, Adverse cardiac events, STEMI, Thrombolysis, Streptokinase.

## Introduction

Acute coronary syndrome (ST elevation myocardial infarction, Non ST elevation myocardial infarction, Unstable angina) is the leading cause of death in developed countries & second leading cause of death in developing countries & by the year 2020 Ischaemic heart disease will hold the first place in the WHO list of leading cause of disability<sup>1</sup>. Coronary artery disease (CAD) is a major cause of death and is a global health problem reaching epidemic in both developed as well as in developing countries<sup>2</sup>. Bangladesh is a small country with vast population. Cardiovascular diseases are becoming a significant burden on health care services in Bangladesh. The prevalence of CAD in Bangladesh has been reported to be 0.33% to 19.6% in different studies. Despite marked disparity in values, there seems to be a rising prevalence and mortality from CAD<sup>3</sup>.

Acute myocardial infarction patients constitute a large proportion of admissions in coronary care unit and their management and risk stratification is of immense importance. In most cases, STEMI is due to rupture of an inflamed thin capped fibro-atheroma containing a lipid rich necrotic core with superimposed thrombosis which results coronary artery occlusion (Stone, 2008). It is well known that inflammation and thrombosis play a crucial role in the pathophysiology of STEMI<sup>4</sup> Vulnerable plaque, characterized by thin fibrous caps, large lipid core, macrophage infiltration and neo-vascularization, is closely related to inflammation<sup>5-6</sup>. The majority of acute coronary syndromes can be attributed to plaque vulnerability<sup>7</sup>.

Platelets are a pivotal component in the process of inflammation and thrombosis. Higher platelet counts may increase thrombocyte activation and aggravate the release of inflammatory mediators, prompting a harmful inflammatory process<sup>8</sup>. In contrast, lymphocytes have been shown to modulate the immunologic response at all

stages of the atherosclerotic process. The association between lower lymphocyte counts and risk of adverse CV outcomes has also been confirmed in previous studies<sup>9-10</sup>.

High PLR was related to increased inflammatory activity and aggravated pro-thrombotic status due to megakaryocytic proliferation and relative thrombocytosis in high –risk with ACS<sup>11-13</sup>. Therefore, High platelet counts have been shown to development of no-reflow via micro-vascular plugging, thrombus formation, and vasoconstriction<sup>14-15</sup>. Leukocytes play a major role in both initiation and progression of atherosclerosis, and have been implicated in acute rupture of atherosclerotic plaques with superimposed thrombus formation<sup>16-21</sup>. Lymphocyte is also a major part of chronic inflammation in the atherosclerotic process. Lymphocyte may express interleukin 10, which plays a significant role in transmigration of mononuclear cells and tissue inhibitor of metalloproteinase 1<sup>22</sup>. Hence, a lower lymphocyte count may be associated with adverse cardiovascular outcomes<sup>23</sup>. Lower lymphocyte levels were associated with advanced heart failure<sup>17, 24</sup> and mortality<sup>20</sup> in STEMI patients.

Higher levels of PLR were also reported to be associated with the slow flow/no-reflow phenomenon<sup>25-26</sup>, increased SYNTAX score<sup>25</sup> impaired infarct-related artery patency<sup>27</sup>, stent restenosis<sup>28</sup>, contrast-induced nephropathy<sup>29</sup>, recurrent non-fatal myocardial infarction<sup>30</sup> and worsening in-hospital and long-term mortality in STEMI<sup>31-33</sup>. PLR may be associated with clinical outcomes such as all-cause mortality, recurrent myocardial infarction, heart failure, serious cardiac arrhythmias, and ischemic stroke in patient with STEMI because an increased PLR was shown to be related to inflammation and atherosclerosis<sup>34</sup>.

## Methodology

This cross sectional descriptive type of study was carried out in the Department of Cardiology, Mymensingh Medical college Hospital, Mymensingh since January 2018 to March 2019. Patient admitted into the Department of Cardiology, MMCH with ST Elevation Myocardial Infarction. Patients with first attack of ST Elevation Myocardial Infarction within 12 hours of onset of chest pain who fulfilled the inclusion and exclusion criteria of study. Non-random purposive sampling method was obtained. Patients with first attack of ST elevation myocardial infarction who were present within 12 hours of onset of chest pain & who were thrombolysed were included in the study.

Patients having previous history of myocardial infarction, having major non-cardiovascular disorder such as sepsis or clinical evidence of active infection, recent (three months) surgery or trauma, recent (three months) steroid therapy and patient at e age (less than 25 years and more than 75 years), having renal impairment, hepatic insufficiency, bleeding diathesis, inflammatory disease, malignancy, having contraindication to thrombolytic therapy and those who do not willing to enroll in study were excluded from the study.

Considering inclusion and exclusion criteria sample population was divided into two groups -

- **Group-I** : Patients with Platelet Lymphocyte Ratio (PLR) <150.
- **Group-II** : Patients with Platelet Lymphocyte Ratio (PLR) >150.

After calculation of the sample size (initially 322) 242 patients were taken but among them, 12 patients shifted to PCI capable center as a pharmaco-invasive strategy, 5 patients died immediately after or during thrombolysis and 8 patients dropped out due to incomplete data. Finally, 217 cases were feasible to be included in the study.

Data were collected by direct interview from patient or attendant and their responses were organized through a structured case record form. After collection data were processed and analyzed by computer software SPSS (Statistical package for social science) Version 22.0. Level of significance was considered as p value less than 0.05 ( $p < 0.05$ ). Continuous data were expressed as mean  $\pm$  SD & categorical data as frequency and percentage. Categorical data were analyzed with  $\chi^2$  test. Student's "t" test was used for analysis of continuous variables.

Comparison between groups was done by unpaired t-test. Multivariate regression analysis was done to find out the association of in-hospital adverse cardiac events with platelet lymphocyte ratio and other compounding variables. Proper safety measures were ensured in every steps of the study. Ethical clearance was obtained from the Institutional Review Board of MMCH to undertake the present study. Informed written consent was obtained from each subject who voluntarily provided consent to participate in the study. The ethical issues were addressed accordingly. Strict confidentiality and security of data related to patient was maintained. There was no potential conflict of interest in this study and was entirely an academic research project.

A 12 lead standard surface ECG on admission was done within 10 min of arriving patient at CCU. Troponin-I ELISA assay kit was used for quantitative determination of cardiac troponin I in human whole blood serum / plasma specimens. Platelet Lymphocyte Ratio (PLR) level was estimated during estimation of Complete Blood Count (CBC) by Automated Haematology Analyzer.

Glucose reagent, cholesterol reagent, triglycerides reagent and creatinine reagent were used for quantitative determination of blood glucose (random, fasting and 2 hours post-prandial), lipid profile and serum creatinine respectively in human whole blood serum / plasma specimens.

Echocardiograms were subjected to careful visual analysis to detect regional contractile abnormalities. LV end-systolic and end-diastolic volumes and LVEF was estimated by Teicholtz method. 2D and Doppler echocardiography imaging were performed to screen for wall motion abnormalities, mitral annular calcification, valvular stenosis and regurgitation. LV wall thickness, diameters, volumes and EF were measured according to American society of Echocardiography (ASE) recommendations. According to LVEF the LV systolic functions were divided into-

<b>Normal LV systolic function</b>	>55%
<b>Mild LV systolic dysfunction</b>	45-54%
<b>Moderate LV systolic dysfunction</b>	30-44%
<b>Severe LV systolic dysfunction</b>	<30%

Facilities available in the Department of Cardiology, MMCH (ECG, Echocardiography) were used. Haematological & Biochemical investigations were carried out in the Department of Clinical Pathology, MMCH and Emergency Biochemistry Lab, Dept. of Cardiology, MMCH.

After collection, data were checked for omission, inadequacy, irrelevancy and inconsistency. Omissions were corrected by retaking history or reexamining the patient. Irrelevant and inconsistent data were discarded.

#### **Variables of the study:**

##### **Demographic variables:**

- Age
- Sex

##### **Risk factors variables:**

- HTN

- DM
- Smoking
- Dyslipidaemia
- Family History Coronary artery Disease
- BMI (kg/m<sup>2</sup>)

**Investigation variables:**

- ECG
- Troponin-I
- CBC
- Echocardiography

**Outcome variables:**

- Arrhythmias
- Heart Failure
- Cardiogenic shock
- Hospital Stay
- In hospital death.

**Results**

This was a cross sectional descriptive study conducted in the Department of Cardiology of Mymensingh Medical College Hospital for a period of fifteen months (15 months) from January 2018 to March 2019. The main objective was to evaluate the association between Platelet-Lymphocyte Ratio (PLR) and In-hospital Outcome in patients with first attack of Acute ST-Segment Elevation Myocardial Infarction (STEMI) Thrombolysed with Streptokinase. Total sample population were 247 but 30 patient was drop out due to referred, death immediately after admission, absconded or not done investigation. So ultimately total 217 patients were taken as sample population.

Total study populations were 217. Among them 64.5% patients were in Group-I: Platelet Lymphocyte Ratio (PLR) <150, n = 140 (male 129, female 11) & 35.5% patients were in Group-II: Platelet Lymphocyte Ratio (PLR) >150, n= 77 (male 69, female 8).

**Table 1: Baseline characteristics of the study population (n=217)**

	<b>Group-I (n=140)</b>	<b>Group-II (n=77)</b>	<b>p-Value</b>
<b>Age</b>	50.78±11.41	55.00±9.98	0.031 <sup>s</sup>
<b>Sex</b>			
Male	129 (92.1%)	69 (89.6%)	0.528 <sup>ns</sup>
Female	11 (7.9%)	8 (10.4%)	
<b>BMI</b>	23.75± 2.15	23.47± 2.14	0.568 <sup>ns</sup>
<b>Risk Factors</b>			

Hypertension	19 (13.6)	27 (35.1)	0.001 <sup>s</sup>
Diabetes	13 (9.3)	16 (20.8)	0.017 <sup>s</sup>
Smoking	116 (82.9)	54 (70.1)	0.029 <sup>s</sup>
Family H/O IHD	9 (6.4)	7 (9.1)	0.473 <sup>ns</sup>
Sedentary Life	41 (29.3)	31 (40.3)	1.007 <sup>ns</sup>
<b>Involved Wall in AMI</b>			
Anterior	43 (30.7)	20 (26.0)	0.325 <sup>ns</sup>
Ext-Ant	22 (15.7)	17 (22.1)	
Inferior	68 (48.6)	35 (45.5)	
Lateral	0 (0)	1 (1.3)	
Ant-Septal	4 (2.9)	4 (5.2)	
Ant-Inf	3 (2.1)	0 (0)	
<b>Troponin-I</b>	25.83±19.35	28.99±20.24	0.261 <sup>ns</sup>

Chi square & Un-paired t-tests were done accordingly.

**s** means significant

**ns** means Non-significant.

**Group-I** : Patients with Platelet Lymphocyte Ratio (PLR) <150

**Group-II** : Patients with Platelet Lymphocyte Ratio (PLR) >150

The Table shows the baseline characteristics of the study population. The mean ages of Group-I was 50.78 ± 11.41 years and Group-II was 55.00 ± 9.98 years. Analysis revealed statistically Significant (p < 0.05) mean age difference between the study groups. Majority of the study population were male. But gender was not found to be statistically significant (p>0.05). BMI showed slightly overweight study population but no statistical significance was found among the groups. Among the risk factors smoking was found to be the highest number followed by hypertension and diabetes. All these risk factors had statistically significant difference among the groups (p<0.05). Although sedentary life and family H/O IHD were found to have a substantial numbers but they were statistically insignificant (p>0.05). Among the involved walls due to myocardial infarction inferior involvement was the highest followed by anterior and extensive anterior but no statistical significance couldn't be drawn among the groups. Troponin-I was also found to be statistically non-significant between the groups (p>0.05)

**Table 2: Platelet Lymphocyte Ratio (PLR) among the study population (n=217)**

	<b>Group-I (&lt;150)</b>	<b>Group-II (&gt;150)</b>	<b>Total</b>
<b>PLR</b>	140 (64.5)	77 (35.5)	217 (100.0)

**Table 2** shows that total study populations were 217. It was observed that in 140 (64.5%) of the study population the PLR level was <150 and 77 (35.5%) of study population the PLR level was >150.

**Table 3: In-hospital outcome analysis among the study population (n=217)**

	<b>Study population</b>				<b>p-value</b>
	<b>Group-I (&lt;150)</b>		<b>Group-II (&gt;150)</b>		
	<b>Count</b>	<b>%</b>	<b>Count</b>	<b>%</b>	

<b>Complications</b>	Yes	30	21.4	49	63.6	0.001 <sup>s</sup>
	No	110	78.6	28	36.4	
<b>Hospital Stay</b>		4.04±1.31		4.81±1.73		0.001 <sup>s</sup>
<b>Arrhythmia</b>	Yes	7	5.0	10	13.0	0.036 <sup>s</sup>
	No	133	95.0	67	87.0	
<b>Heart failure</b>	Yes	21	15.0	35	45.5	0.001 <sup>s</sup>
	No	119	85.0	42	54.5	
<b>Cardiogenic shock</b>	Yes	5	3.6	8	10.4	0.043 <sup>s</sup>
	No	135	96.4	69	89.6	
<b>Death</b>	Yes	9	6.4	7	9.1	0.473 <sup>ns</sup>
	No	131	93.6	70	99.9	

Chi-square & Unpaired t- tests were done accordingly.

**s** means significant

**ns** means Non-significant.

**Group –I** : Patients with Platelet Lymphocyte Ratio (PLR) <150

**Group –II** : Patients with Platelet Lymphocyte Ratio (PLR) >150

Above table shows outcome of study population according to Platelet Lymphocyte Ratio (PLR) level. Complications occurred in Group-I 21.4% and that is Group-II 63.6%, which was statistically significant ( $p < 0.05$ ). Arrhythmias, Heart failure, Cardiogenic shock occurred in 5.0%, 15.0%, 3.6%, in group- I where as in group-II Arrhythmias Heart failure, Cardiogenic shock, occurred in 13.0%, 45.5%, 10.4%, respectively, which were statistically significant ( $p < 0.05$ ). Regarding death occurred in 6.4% in Group-I where as in Group-II 9.1% which were statistically not significant ( $p > 0.05$ ). The mean duration of hospital stay in group-I was (4.04±1.31) days & in group-II was (4.81±1.73) days. p-Value of hospital stay was statistically significant ( $p < 0.05$ ).

**Table 4: Left ventricular ejection fraction among Heart Failure patients of study population (n=59)**

<b>Heart failure</b>	<b>Study population</b>		<b>p-Value</b>
	<b>Group-I (PLR &lt;150) n1=23</b>	<b>Group-II (PLR &gt;150) n2=36</b>	
Ejection fraction in percent	51.41±11.39	46.08±8.21	0.001 <sup>s</sup>

Unpaired t-test was done to measure the level of significance.

n1=number of heart failure patient in group -I.

n2=number of heart failure patient in group-II.


**Table 4** shows left ventricular mean ejection fraction among patients who developed heart failure. In group-I mean ejection fraction was  $(51.41 \pm 11.39)$  % and in Group-II mean ejection fraction was  $(46.08 \pm 8.21)$  %. From above table, P-value of two groups was statistically significant ( $p < 0.05$ ).

**Table 5: Killip class among heart failure patients of Study Population (n=59)**

Killip Class	Study population				p- Value
	Group-I (PLR<150)		Group-II (PLR>150)		
	Frequency	%	Frequency	%	
I	1	4	1	3	0.001 <sup>s</sup>
II	12	52	9	25	
III	4	18	17	47	
IV	6	26	9	25	
<b>Total</b>	23	100.0%	36	100.0%	

Chi-square test was done.

**Table 5** shows Killip class among study population who developed heart failure. In group-I Killip Class= 1, Killip Class=2, Killip Class=3, Killip Class=4 were 4.0%, 52.0%, 18.0%,26.0% patients where as in Group- II that was 3.0%, 25.0%, 47.0%, 25.0% patients. From above table, p- value of two group was statistically significant ( $p < 0.05$ ).



**Figure 1:** In-hospital adverse outcomes in two groups.

**Group-I** : Patients with Platelet Lymphocyte Ratio <150.

**Group-II** : Patients with Platelet Lymphocyte Ratio >150.

This figure (**Figure 1**) shows in Group-I, 21.4 % patients developed in-hospital adverse cardiac events, and in Group-II, 63.6% patients developed adverse cardiac events.

**Table 6: Multivariate regression analysis for evaluating PLR to predict In-hospital adverse cardiac events compared to other predictors:**

Model	Unstandardized Coefficients		Standardized Coefficients	T	Sig.	
	B	Std. Error	Beta			
1	(Constant)	2.583	.573		4.505	.000
	Age	-.004	.003	-.089	-1.328	.186
	Sex	-.097	.123	-.057	-.783	.434
	Smoking	.051	.086	.044	.591	.555
	HTN	.039	.081	.033	.479	.633
	DM	-.054	.093	-.038	-.578	.564
	Dyslipidemia	.090	.070	.087	1.282	.201
	Family H/O IHD	-.029	.122	-.016	-.236	.813
	Sedentary life	-.080	.067	-.078	-1.184	.238
	BMI	-.014	.016	-.060	-.877	.381
	PLR	-.002	.000	-.380	-5.727	<.001**

a. Dependent Variable: Complications

In the above table, logistic regression was used to study the impact of PLR level and other confounders like age, sex, smoking, hypertension, diabetes, dyslipidemia, sedentary life and body mass index (BMI) in predicting in-hospital outcomes in first attack of ST-segment elevation myocardial infarction patients thrombolysed with

streptokinase. After performing the multivariable logistic regression analysis, it was found that Platelet Lymphocyte Ratio (PLR) contributed to predict adverse In-hospital cardiac events with p value 0.001. From the above parameters, it is found that PLR level is the most independent predictor of adverse In-hospital cardiac events.

## Discussion

Majority of patients of both groups were 45-55 years. Few studies of similar type reported the mean age of the patients were 58.1( $\pm$ 9.1) years, 57.58( $\pm$ 9.23) years, 62( $\pm$ 12) years respectively<sup>36-38</sup>. This finding is almost similar to the present study.

In our study, out of 217 cases, 198 (91.24%) were male. In a similar study it was found 84.80 % cases were male<sup>32</sup>. So, like other studies, males were predominant in our study also.

In this study smoking status was statistically significant ( $p < 0.05$ ) between two groups of the study population. A study conducted in NICVD, Dhaka, reported that commonest risk factor of AMI was smoking and it was 73.33%<sup>39</sup>.

In this study, hypertension was statistically significant ( $p < 0.05$ ) risk factor. A study of similar type and reported that near half of their study population were hypertensive<sup>40</sup>. Another conducted study regarding risk factor assessment for coronary artery disease and reported that majority of the study population were hypertensive<sup>39</sup>.

In this study, diabetes mellitus was found statistically significant ( $p < 0.05$ ). Although in both group, non-diabetic patients were predominant. Similar findings were found in other study<sup>40</sup>.

It was observed that in 140(64.5%) of study population PLR level were  $< 150$  and 77(35.5%) of study population PLR level were  $> 150$ . In our study the mean Platelet Lymphocyte Ratio (PLR) were statistically significant ( $P < 0.05$ ). Similar conducted study with nearly similar to the present study<sup>36</sup>.

On evaluation of In-hospital outcomes of study population revealed Group-II population developed statistically significant more in-hospital adverse cardiac events than its counterpart.

Our study showed that during hospital stay composite end-point rates of arrhythmia and Heart failure were statistically significant ( $p = 0.024$ ). In similar study reported that rate of heart failure in low PLR group was significantly higher than high PLR group ( $p < 0.05$ )<sup>41</sup>.

Regarding sub-group analysis of heart failure among study population showed majority resided in Killip class II & III. Our study showed that low PLR associated with lower Killip class and high PLR associated with worst Killip class, which was statistically significant. A similar study reported that patients in the highest PLR tertile had a worse presentation than those in lowest PLR tertile<sup>42</sup>. Our study also found that the mean LV systolic function was more depressed in more PLR group than that of lower PLR group and hence the outcome.

The rate of cardiogenic shock among study population was statistically significant. The PLR may be associated with clinical outcomes (such as all-cause mortality, recurrent myocardial infarction, heart failure, serious cardiac arrhythmia, and ischemic stroke) in patients with STEMI, because an increased PLR was known to be related to inflammation and atherosclerosis<sup>36</sup>.

In our study, we found that the in-hospital mortality rates among the study population was not statistically significant. A study on prognostic value of PLR in patients with STEMI revealed that the in-hospital mortality rates were significantly more in high PLR group than that of low PLR group<sup>40</sup>. In our study the mean duration of hospital stay (in Days) were also found significantly higher in high PLR group than low PLR group.

From the above discussion we found that patient with admission high platelet lymphocyte ratio (PLR) with first attack of acute STEMI who were thrombolysed with streptokinase had higher risk for development of in-hospital cardiovascular events (heart failure, arrhythmia, cardiogenic shock) and increased hospital stay. Thus platelet lymphocyte ratio (PLR) had positive correlation with in-hospital adverse cardiac events in patients with first attack of acute STEMI.

## Conclusion

The present study concluded that admission Platelet lymphocyte ratio (PLR) associated with In-hospital adverse cardiac events following thrombolysis in patients with first attack of ST-segment elevation myocardial infarction (STEMI). This study positively correlated with in-hospital adverse cardiac events in STEMI patients following thrombolysis. Thus high PLR is a strong and independent predictor of in-hospital adverse cardiac events in STEMI patients treated with thrombolytics. The study team also showed that this simple, widely available and inexpensive test might help to identify STEMI patients who are at a higher risk of in-hospital death and developing major adverse cardiovascular events (MACE) and may help in risk stratification of these cases. We think that the significant findings of our analysis can serve as a guide for future clinical practice.

## Limitations of the study

This study was not without limitations. The limitations of the study were as follows

- This study was conducted in only one center (Department of Cardiology, Mymensingh Medical College Hospital) and majority of study population was male. Thus, these results need to be re-evaluated in other health care center by inclusion of male and female in large numbers.
- The sample size was small and study period was short.
- We used streptokinase as thrombolytic regimen in all of our patients. Streptokinase has lower potency compared to the other clinically available thrombolytic drugs in restoring flow in the culprit coronary artery. Streptokinase is the only readily available thrombolytic routinely used in our center.
- Though re-infarction or ongoing MI is an important outcome in STEMI patients but it could not be evaluated due to technical problem.
- We did not compare the prognostic value of PLR with other inflammatory markers like hs-CRP, pro-BNP and etc.

## References

1. Murray CJ, Lopez AD (1997). Mortality by cause for eight regions of the world; global burden of disease study. *Lancet* 349: 1269-1276.
2. Chaturvedi, V. & Bhargava, B. 2007. Health care delivery for coronary heart disease in India where are we headed? *Am Heart Hospital Journal*. vol. 5, 32-37.
3. Islam, A.K.M., Mohibullah, A.K.M., Paul, T., (2016). Cardiovascular Disease in Bangladesh: A Review. *Bangladesh Heart Journal*, vol.31, no.2, 80-99.
4. Mohlenkamp S, Lehmann N, Moebus S, Schmermund A, Dragano N, Stang A et al. (2011) Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. *J Am Coll Cardiol*;57(13):1455-1464.
5. Hansson GK, Libby P, Tabas I. (2015) Inflammation and plaque vulnerability. *J Intern Med*;278:483-93.
6. Newby AC, George SJ, Ismail Y, Johnson JL, Sala-Newby GB, Thomas AC. (2009) Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. *Thromb Haemost*;101:1006-11.
7. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. (2000) Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. *Arterioscler Thromb Vasc Biol*. 20:1262-75.
8. Ibrahim H, Schutt RC, Hannawi B, DeLao T, Barker CM, Kleiman NS. (2014) Association of immature platelets with adverse cardiovascular outcomes. *J Am Coll Cardiol*;64(20):2122-2129.
9. Nunez J, Sanchis J, Bodi V, Nunez E, Heatta AM, Minana G, et al. (2009) Therapeutic implications of low lymphocyte count in non-ST segment elevation acute coronary syndromes. *Eur J Intern Med*;20(8):768-774.
10. Aghdaii N, Ferasatkish R, Mohammadzadeh Jouryabi A, Hamidi SH. (2014) Significance of preoperative total lymphocyte count as a prognostic criterion in adult cardiac surgery. *Anesth Pain Med*;4(3):e20331.

11. Fuentes Q E, Fuentes Q F, Andrés V, Pello OM, Font de Mora J, Pabon P. (2013) Role of platelets as mediators that link inflammation and thrombosis in atherosclerosis. *Platelets*. Indexed in Pubmed: 24(4),255-262.
12. Gonzalez-Porrás JR, Martín-Herrero F, Gonzalez-Lopez TJ, Olazobal J, Diez-Campelo M, Pabon P, et al. (2010) The role of immature platelet fraction in acute coronary syndrome. *Thromb Haemost*, 103(1): 247–249.
13. Lindemann S, Krämer B, Seizer P, Gawaz M. (2007) Platelets, inflammation and atherosclerosis. *J Thromb Haemost*, 5 Suppl 1: 203–211.
14. Choi S.W., Choi D.H., Kim H.W., Ku Y.H., Ha S., Park G., et al. (2014) Clinical outcome prediction from mean platelet volume in patients undergoing percutaneous coronary intervention in Korean cohort: Implications of more simple and useful test than platelet function testing. *Platelets*; 25(5): 322-327.
15. Verdoia M, Secco GG, Barbieri L, et al. (2014) Novara Atherosclerosis Study Group (NAS). Platelet HPA-1 a/HPA-1 b polymorphism and the risk of periprocedural myocardial infarction in patients undergoing elective PCI. *Platelets*. 25(5): 367–372.
16. Bhat T, Teli S, Rijal J, Bhat H, Raza M, Khoueiry G, Meghani M, Akhtar M and Costantino T (2013). Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. *Expert Rev Cardiovasc Ther*; 11: 55-59.
17. Dragu R, Khoury S, Zuckerman R, Suleiman M, Mutlak D, Agmon Y, et al. (2008) Predictive value of white blood cell subtypes for long-term outcome following myocardial infarction. *Atherosclerosis*; 196: 405-412.
18. Chia S, Nagurney JT, Brown DF, Raffel OC, Bamberg F, Senatore F, Wackers FJ and Jang IK. (2009) Association of leukocyte and neutrophil counts with infarct size, left ventricular function and outcomes after percutaneous coronary intervention for ST-elevation myocardial infarction. *Am J Cardiol*; 103: 333-337.
19. Lee GK, Lee LC, Chong E, Lee CH, Teo SG, Chia B, et al. (2012) The long-term predictive value of the neutrophil-to-lymphocyte ratio in Type 2 diabetic patients presenting with acute myocardial infarction. *Qjm*; 105: 1075-1082.
20. Cho KH, Jeong MH, Ahmed K, Hachinohe D, Choi HS, Chang SY, et al. (2011) Value of early risk stratification using hemoglobin level and neutrophil-to-lymphocyte ratio in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Am J Cardiol*; 107: 849-856.
21. Papa A, Emdin M, Passino C, Michelassi C, Battaglia D, Cocci F. (2008) Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. *Clin Chim Acta*; 395(1-2):27-31.
22. Van Diepen S, Vavalle JP, Newby LK, Clare R, Pieper KS, Ezekowitz JA, et al. (2013) The systemic inflammatory response syndrome in patients with ST-segment elevation myocardial infarction. *Crit Care Med*; 41(9):2080-2087.
23. Zouridakis EG, Garcia-Moll X, Kaski JC. (2000) Usefulness of the blood lymphocyte count in predicting recurrent instability and death in patients with unstable angina pectoris. *Am J Cardiol*. 86(4):449-451.
24. Uthamalingam S, Patvardhan EA, Subramanian S, Ahmed W, Martin W, Daley M and Capodilupo R (2011). Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. *Am J Cardiol* 107: 433-438.
25. Kurtul A, Yarlioglu M, Murat SN, Ergun G, Duran M, Citiin M, et al. (2014) Usefulness of the platelet-to-lymphocyte ratio in predicting angiographic reflow after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. *Am J Cardiol*; 114(3):342-347.
26. Akboga MK, Canpolat U, Balci KG, Akyel A, Sen F, Yayla C. (2016) Increased platelet to lymphocyte ratio is related to slow coronary flow. *Angiology*; 67(1):21-26.
27. Yayla C, Akboga MK, Canpolat U, Akyle A, Dogan M, Yeler E et al. (2015) Platelet to lymphocyte ratio can be a predictor of infarct-related artery patency in patients with ST-segment elevation myocardial infarction. *Angiology*, 66(9):831-836.

28. Yilmaz S, Sen F, Unal S, Yayla C, Ozeke O, Aras D, et al. (2015) Usefulness of the platelet-to-lymphocyte ratio in predicting bare-metal stent restenosis. *Scand Cardiovasc J*,49(1):39-44.
29. Demircelik MB, Kurtul A, Ocek H, Cakmak M, Ureyen C, Eryonucu B. (2015) Association between platelet-to-lymphocyte ratio and contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome. *Cardiorenal Med*;5(2):96-104.
30. Ozcan Cetin EH, Cetin MS, Aras D, Topaloglu S, Teinzhan A, Ksacik HK, et al. (2016) Platelet to lymphocyte ratio as a prognostic marker of in-hospital and long-term major adverse cardiovascular events in ST Segment elevation myocardial infarction. *Angiology*,67(4):336-345.
31. Akkaya E, Gul M, Ugur M. (2014) Platelet to lymphocyte ratio: A simple and valuable prognostic marker for acute coronary syndrome. *Int J Cardiol*,177(2):597-598.
32. Ugur M, Gul M, Bozbay M, Cicek G, Uyaral H, Koraglu B, et al. (2014) The relationship between platelet to lymphocyte ratio and the clinical outcomes in ST elevation myocardial infarction underwent primary coronary intervention. *Blood Coagul Fibrinolysis*. 25(8):806-811.
33. Cicek G, Acikgoz SK, Bozbay M, Altay S, Ugur H, Uyarel H, et al. (2015) Neutrophil-lymphocyte ratio and platelet lymphocyte ratio combination can predict prognosis in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Angiology*,66(5):441-447.
34. Balta S, Ozturk C. (2015) The platelet-lymphocyte ratio: a simple, inexpensive and rapid prognostic marker for cardiovascular events. *Platelets*; 26(7):680.
35. Chowdhury, A.W., Alam, N., Khan, H.I.L.R., Sabah, K.M.N., Amin, M.G. (2015) The Pattern of Cardiac Disease at Coronary Care Unit of Dhaka Medical College Hospital. *Cardiovascular Journal*, 7(2), 119-122.
36. Sun Xi.P., Li J., , Zhu W., Li D.B, Chen H., Li H.W. (2017) Impact of Platelet-to-Lymphocyte Ratio on Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction *Angiology*, Vol. 68(4) 346-353.
37. Seyis S, Gunay S, Rencuzoglu I. (2017) Relationship between platelet to lymphocyte ratio and coronary angiography timing in patients with NSTEMI. *Biomedical Research*; 28 (20): 8945-8950.
38. Yüksel M., Yıldız A., Oylumlu M., Akyüz A., Aydın M., (2015) The association between platelet/lymphocyte ratio and coronary artery disease severity *Anatol J Cardiol*; 15: 640-7).
39. Patwary, MSR., Reza, AQM., Mohibullah, AKM., et al., (2008) Prolonged QRS duration of AMI patients indicative of left ventricular systolic dysfunction. *Chest and Heart journal*, 31: 36-39.
40. Oylumlu M, Yıldız A, Oylumlu M, Yüksel M, Polat N, Bilik M.Z., et al. (2015) Platelet-to-lymphocyte ratio is a predictor of in-hospital mortality patients with acute coronary syndrome (*Anadolu Kardiyol Derg*; 15(0): 000-000).
41. Temiz A., Gazi E., Gungor O., Barutcu A., Altun B., Bekler A., et al. (2014) Platelet /Lymphocyte ratio and risk of in hospital mortality in patients with ST-elevated myocardial infarction. *Med Sci Monit.*,20:660-665.
42. Azab B., Shah N., Akerman M., Joseph T. McGinn Jr., (2012) Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. *J Thromb Thrombolysis* 34:326-334.